# tirzepatide

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/tirzepatide-product
Canonical HTML page: https://getbiobrief.com/entity/tirzepatide-product

## Timeline

- **2026-04-14**: JPM Earnings — JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
- **2026-04-10**: FDA Decision Date — Expected regulatory ruling on orforglipron oral weight loss drug.
- **2023**: Zepbound Approval — FDA expands tirzepatide approval to include chronic weight management.
- **2022**: Mounjaro Launch — Tirzepatide enters the market for Type 2 Diabetes treatment.

## Recent coverage (3 stories)

### Eli Lilly Faces Critical April 10 FDA Decision on Oral Weight Loss Candidate
2026-03-23 00:14:59 · Sentiment: Positive · Impact: 7/10 · Sources: 5

Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Full story: https://getbiobrief.com/story/eli-lilly-orforglipron-fda-decision-april-catalyst

### Eli Lilly Warns of Impurities in Compounded Tirzepatide Amid Supply Shortage
2026-03-13 01:01:14 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Eli Lilly has identified hazardous impurities in unapproved, compounded versions of its blockbuster weight-loss drugs, Mounjaro and Zepbound. The pharmaceutical giant is warning patients and providers about significant safety risks as compounding pharmacies continue to exploit ongoing supply shortages.
Full story: https://getbiobrief.com/story/lilly-compounded-tirzepatide-impurity-warning

### Eli Lilly and Veeva Lead 2026 Growth Outlook Amid AI-Driven Pharma Shift
2026-03-04 04:11:43 · Sentiment: Positive · Impact: 6/10 · Sources: 2

As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
Full story: https://getbiobrief.com/story/eli-lilly-veeva-2026-growth-outlook

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.